Kratom, Mitragynine & 7-OH: Safety and Efficacy vs. The Alternatives
What the published record actually shows about deaths, therapeutic window, and pain relief — compared with pharmaceutical opioids, OTC analgesics, and popular herbal options · 2026
What this page is. A data-first comparison, every figure sourced below. It does not claim kratom is harmless — dependence and withdrawal are real, concentrated 7-OH products carry more risk than raw leaf, and the death counts below deserve their caveats. The claim it does make, with the record behind it: on the numbers regulators themselves publish, kratom and its alkaloids sit at the very bottom of the harm scale among the analgesics people actually use, while delivering relief that published studies describe as strong, fast, and — above all — reachable without a prescriber. Related reading: the political story of how these compounds were scheduled anyway.
1. The Pharmacology: Why Potency Doesn't Mean Lethality Here
Kratom's active alkaloids — mitragynine, its oxidized derivative 7-hydroxymitragynine (7-OH), and the semi-synthetic mitragynine pseudoindoxyl — are indeed potent mu-opioid receptor agonists. 7-OH binds with substantially higher affinity than morphine; regulators recite this constantly. What they omit is the mechanism that separates these compounds from the opioids that kill: signaling bias. The mu-opioid receptor drives two distinct downstream pathways, and Kruegel et al. (JACS, 2016) showed mitragynine, 7-OH, and related compounds are G-protein biased — they strongly activate the G-protein cascade that produces analgesia while recruiting β-arrestin-2, the pathway implicated in respiratory depression, only weakly. Classical opioids activate both, hard.
Both receptor classes bind the same target; what differs is which internal switch they throw. The lethal pathway of opioid overdose is the one the kratom alkaloids barely engage. Preclinical follow-ups (including respiratory-depression ceiling work in rodents) support the translation of this bias into a survival advantage; confirmatory human controlled trials remain limited — an honest gap this page flags rather than hides.
This is why "7-OH is 10× more potent than morphine at the receptor" and "7-OH is dramatically harder to die from than morphine" can both be true. Binding affinity measures how tightly the key fits the lock, not which doors open.
2. The Death Comparison, All the Way Up the Scale
The first article charted kratom against OTC analgesics. Here is the same log-scale exercise with the full set of analgesic and recreational options, using the agencies' own numbers.
Read the gap between rows 8, 9, 10 and everything above them. The three kratom rows aren't even annual national totals — they're a 27-state surveillance window — and they still sit 2–3 orders of magnitude below every scheduled or OTC comparator. Normalized per user, the gap widens: alcohol kills ~127 per 100,000 drinkers per year; kratom's surveillance numbers annualize to roughly 3 per 100,000 users — nearly all with fentanyl or other drugs on board. On a linear scale the tobacco bar would run off this page three times and the kratom bars would be thinner than the line drawing them.
3. Efficacy: What Users Actually Report, and Why They Report It
The most granular published data on kratom as an analgesic is the Journal of Pain ecological-momentary-assessment study (Mun et al., 2024): 395 regular consumers surveyed, 357 tracked in real-time for 15 days. It wasn't a pain study by design — participants were recruited on kratom use alone — yet nearly half turned out to be chronic pain patients, and the pain findings were unambiguous.
93.2%
reported pain relief over weeks/months of regular use (J Pain 2024)
80.3/100
mean self-rated strength of that relief — "strong," onset in minutes to hours
69.2%
said difficulty obtaining adequate pain treatment drove them to kratom
58.4%
of chronic-pain participants' daily use days: pain relief was the #1 motivation
Apples-to-oranges caveat, stated plainly: the kratom figure is self-reported relief in a naturalistic cohort; the ~30% figure is the share of chronic-pain patients in clinical trials achieving the stricter bar of ≥50% pain reduction on opioid therapy (meta-analytic literature, e.g., Turk et al., Pain 2011). Different measures, different bars. But the pairing still makes the fair point: a substance regulators call "highly abusable and without medical use" is, in the only granular field data that exists, delivering strong relief to nearly everyone who takes it for that reason — at a fraction of the mortality of the prescription alternative, and with real-time EMA data confirming recent use tracks with lower momentary pain.
Against the OTC and herbal field, the comparison is starker still. Acetaminophen's effect on chronic pain conditions is minimal (the Lancet osteoarthritis network analysis found it effectively indistinguishable from placebo for hip/knee OA pain). Curcumin/turmeric trials show small, inconsistent effects. Kava has moderate evidence for anxiety, weak-to-none for pain. Valerian is a sleep aid with mixed evidence and no analgesic claim. CBD's analgesic evidence remains thin outside seizure indications. None of these address severe, opioid-responsive pain. That is the entire point: for the severe-pain patient abandoned by the prescription system, the realistic menu was never "kratom versus oxycodone" — it was kratom versus nothing.
Option
Analgesic evidence
Annual U.S. deaths (est.)
Access
Rx opioids (oxycodone class)
Strong; ~30% of chronic patients reach ≥50% relief
10,112 (2023) + diversion into synthetic supply
Gatekeeper-dependent; force-tapers common
Heroin / illicit fentanyl
Strong
3,984 + ~73,000 synthetic-opioid deaths
Illegal, potency-uncontrolled
NSAIDs (ibuprofen class)
Moderate; ceiling effect; poor fit for severe pain
5,000–16,500 (GI bleed; CV events additional)
OTC
Acetaminophen
Weak for chronic pain; ~placebo in OA
~500 (liver failure; 56,000 ER visits)
OTC; narrow therapeutic window
Kava / valerian / chamomile
Anxiety/sleep only; no meaningful analgesia
No established estimates; rare idiosyncratic liver events (kava)
OTC
Turmeric / curcumin
Small, inconsistent effects in OA trials
Essentially none attributed
OTC
CBD
Thin outside seizures
Essentially none attributed directly
OTC (gray-market purity)
Kratom leaf / mitragynine
93.2% user-reported relief, 80/100 strength, EMA-confirmed; centuries of traditional use
0 confirmed sole-cause (7-only-on-tox cases all showed co-drugs on follow-up)
OTC — the access point under attack
Concentrated 7-OH
Same mechanism, higher potency; the form severe-pain patients rely on when leaf is insufficient
Same surveillance data (not separated by form); dependency risk higher than leaf
Now felony-scheduled federally in most concentrated forms
4. The Honest Column: What Can Go Wrong
Dependence is real. Regular users develop tolerance and experience a withdrawal syndrome on cessation — flu-like, shorter and generally milder than classical opioid withdrawal, but genuinely unpleasant and well documented in the literature. Concentrated 7-OH products, engineered for maximal receptor occupancy, carry higher dependence risk than raw leaf, and the survey record shows a minority of long-term users report difficulty moderating use. Other real concerns: impairment while driving under its effects, unregulated product contamination (heavy metals, salmonella) in an unsupervised market, and drug interactions. None of this is in tension with the death data above — "not lethal" and "not consequence-free" are different claims. A rational regulatory regime would address these with labeling, testing, age gates and honest packaging. Emergency felony scheduling addresses them by making the user a criminal.
How does kratom dependence actually stack up? The best published prevalence work applies DSM-5 substance-use-disorder criteria directly: a 2023 survey of 2,061 consumers (Hill et al., J Addict Med 2024) found 25.5% met kratom use disorder criteria — with tolerance (81.3%) and withdrawal (68.0%) the dominant symptoms, and most cases mild or moderate; an earlier 2017 survey put it at 12.3%. Among daily/near-daily users in the EMA cohort, KUD prevalence was 66.7% — yet even there, the criteria met were overwhelmingly tolerance/withdrawal, interference-with-life symptoms were rare, and psychosocial functioning remained intact for the plurality of consumers. Put that against the same measure for the legal and therapeutic alternatives:
The honest read: kratom is not dependence-free, and among daily users its DSM-criteria rate resembles nicotine's. But three things keep it out of the class of the substances it's being equated with: (1) the typical consumer's rate (12–26%) sits alongside alcohol and cannabis, substances sold at every gas station; (2) the criteria driving kratom's numbers are overwhelmingly tolerance and withdrawal — the "loss of control / life interference" symptoms that define destructive addiction are rare even in the daily cohort, whose functioning the researchers specifically noted remained intact; and (3) severity skews mild-to-moderate, with withdrawal shorter and generally milder than classical opioids. Pair this chart with the death chart above: kratom trades a nicotine-like dependence profile for a near-zero mortality profile — while nicotine kills ~480,000 a year.Every option plotted on the two axes a pain patient actually weighs: does it work, and will it own me. The upper-right is the corner regulators claim to be protecting — high benefit, low dependence. That's where kratom sits. The substances legally sold on every corner cluster left. The prescription class that kratom is being equated with is both more dependence-forming and less often effective for the patients who can actually obtain it.
5. Conclusion: The Inverted Pyramid
Rank the analgesic options Americans actually use by deaths: tobacco (if one counts nicotine as an analgesic-adjacent crutch) and alcohol sit at half a million combined; the prescription opioid class at five digits; the OTC painkillers at a combined ~17,000; kratom at zero confirmed sole-cause fatalities in the entire surveillance record. Rank them by access for the untreated severe-pain patient, and kratom is alone at the top precisely because everything stronger is gatekept and everything open is too weak. Rank them by intensity of federal enforcement effort in 2025–2026, and kratom and 7-OH — the bottom-left corner of both distributions — get emergency Schedule I treatment while the killers get subsidies and tax credits.
Mun CJ, Panlilio LV, Dunn KE, et al. Kratom use for self-management of pain: cross-sectional and EMA data. J Pain (2024) · jpain.org (93.2% relief; 80.3/100; 69.2% access barrier; 49.1% chronic pain)
Kruegel AC, Gassaway MM, Kapoor A, et al. Synthetic and receptor signaling explorations of the mitragyna alkaloids. J Am Chem Soc (2016) — mitragynine/7-OH G-protein bias vs β-arrestin recruitment.
Olsen A, et al. Unintentional Drug Overdose Deaths Involving Kratom — CDC MMWR / SUDORS (2019) · cdc.gov (152 positive; 91 involved; 7 only-substance)
Gershman K, et al. Deaths in Colorado involving mitragynine. Clin Toxicol (2019) — co-drugs found in all available "kratom-only" samples.
Frontiers in Pharmacology (2024): Kratom safety and toxicology in the public health context · doi.org/10.3389/fphar.2024.1403140 (NPDS ratios; NIDA death tally history)
Singh G, et al.; FDA/CDER risk estimates — NSAID GI mortality 5,000–16,500/yr; acetaminophen ~500 deaths/yr (LiverTox; Asterisk/dynomight summaries of FDA figures)
Turk DC, et al. Treatment of nonmalignant chronic pain: meta-analytic ~30% ≥50% relief on opioids. Pain (2011).
Grundmann O, et al. Self-reported health diagnoses and correlates with kratom use, N=8,049 · pubmed 31567595
Hill K, Grundmann O, Smith KE, Stanciu CN. Prevalence of Kratom Use Disorder Among Kratom Consumers. J Addict Med 2024;18(3):306–312 · doi.org/10.1097/adm.0000000000001290 (KUD 25.5%; tolerance 81.3%, withdrawal 68.0%)
Smith KE, et al. (2017 survey) & Current Psychiatry Reports (2024) review of KUD assessment, incl. EMA daily-user cohort (KUD 66.7%, functioning intact) · link.springer.com